KR20120104165A - 암 치료용 화합물 및 조성물 - Google Patents

암 치료용 화합물 및 조성물 Download PDF

Info

Publication number
KR20120104165A
KR20120104165A KR1020127007113A KR20127007113A KR20120104165A KR 20120104165 A KR20120104165 A KR 20120104165A KR 1020127007113 A KR1020127007113 A KR 1020127007113A KR 20127007113 A KR20127007113 A KR 20127007113A KR 20120104165 A KR20120104165 A KR 20120104165A
Authority
KR
South Korea
Prior art keywords
compound
cell
cancer
independently selected
compounds
Prior art date
Application number
KR1020127007113A
Other languages
English (en)
Korean (ko)
Inventor
마이클 앤드류 폴리
로버트 굴드
피터 엘리엇
안나 맨디노바
샘 리
Original Assignee
매사추세츠 제네럴 호스피털 코퍼레이션
캔테라 테라퓨틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 매사추세츠 제네럴 호스피털 코퍼레이션, 캔테라 테라퓨틱스 인코퍼레이티드 filed Critical 매사추세츠 제네럴 호스피털 코퍼레이션
Publication of KR20120104165A publication Critical patent/KR20120104165A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020127007113A 2009-09-02 2010-09-02 암 치료용 화합물 및 조성물 KR20120104165A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27575409P 2009-09-02 2009-09-02
US61/275,754 2009-09-02

Publications (1)

Publication Number Publication Date
KR20120104165A true KR20120104165A (ko) 2012-09-20

Family

ID=43625764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007113A KR20120104165A (ko) 2009-09-02 2010-09-02 암 치료용 화합물 및 조성물

Country Status (9)

Country Link
EP (1) EP2473506A4 (fr)
JP (1) JP2013503888A (fr)
KR (1) KR20120104165A (fr)
CN (1) CN102625805A (fr)
AU (1) AU2010289493A1 (fr)
BR (1) BR112012004701A2 (fr)
CA (1) CA2772614A1 (fr)
IN (1) IN2012DN01878A (fr)
WO (1) WO2011028860A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160007724A (ko) 2014-06-25 2016-01-21 서울대학교산학협력단 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물
KR20200081633A (ko) 2018-12-27 2020-07-08 주식회사 티에스디라이프사이언스 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201715008D0 (en) * 2017-09-18 2017-11-01 Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa TRPV2 Antagonists
CN110002987B (zh) * 2019-03-22 2020-09-15 南通大学 苯基亚烯丙基环己烯酮衍生物及制备方法和用途
CN117229205A (zh) * 2023-09-14 2023-12-15 中国医学科学院基础医学研究所 苯基丙烯酰胺类rhbdd1抑制剂制备方法及制药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478901A3 (fr) * 2007-02-14 2012-11-14 Mars Incorporated Composés neurogènes
US20100093613A1 (en) * 2007-03-09 2010-04-15 Kunkel Eric J Methods for identifying agents and their use for the prevention or stabilization of fibrosis
CN102146054A (zh) 2010-02-10 2011-08-10 新昌县来益科技开发有限公司 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160007724A (ko) 2014-06-25 2016-01-21 서울대학교산학협력단 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물
KR20200081633A (ko) 2018-12-27 2020-07-08 주식회사 티에스디라이프사이언스 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물

Also Published As

Publication number Publication date
WO2011028860A3 (fr) 2011-07-21
AU2010289493A1 (en) 2012-04-19
CA2772614A1 (fr) 2011-03-10
EP2473506A2 (fr) 2012-07-11
CN102625805A (zh) 2012-08-01
WO2011028860A2 (fr) 2011-03-10
IN2012DN01878A (fr) 2015-08-21
JP2013503888A (ja) 2013-02-04
BR112012004701A2 (pt) 2018-06-12
EP2473506A4 (fr) 2013-03-06

Similar Documents

Publication Publication Date Title
US8349832B2 (en) Compounds and compositions for treating cancer
US8318737B2 (en) Compounds and compositions for treating cancer
TWI679201B (zh) 吡唑并嘧啶化合物
JP4172726B2 (ja) シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
AU720704B2 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
US20080125380A1 (en) Fatty acid-anticancer conjugates and uses thereof
KR20050012722A (ko) (+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온: 그것의 조성물 및 사용방법
US10604510B2 (en) Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof
KR20120104165A (ko) 암 치료용 화합물 및 조성물
US20130237539A1 (en) Compounds and Compositions for Treating Cancer
KR20090112720A (ko) 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
US9809621B2 (en) Stable peptide-based PACE4 inhibitors
WO2000067802A1 (fr) Compositions d'acides gras -n-substituted indol-3-glyoxyl-amide et leur utilisation
JP6095857B2 (ja) ピラゾロピリミジン化合物
KR100898330B1 (ko) 항암성을 갖는 새로운 플라보노이드 유도체 7-ｏ-(3-벤질옥시프로필)-5,4' -ｏ-디메틸-아피제닌, 그 제법 및 그것을 포함하는 항암 조성물
US20060199835A1 (en) Neuroprotective and anti-proliferative compounds
US10646479B2 (en) Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer
WO2006063762A1 (fr) Nitriles de dipeptides

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid